As a result of research, high prevalence of arterial hypertension has been identified in the group of patients with coronary heart disease aged 60 and older. Most often, occurring form of arterial hypertension among g...As a result of research, high prevalence of arterial hypertension has been identified in the group of patients with coronary heart disease aged 60 and older. Most often, occurring form of arterial hypertension among geriatric patients is isolated systolic arterial hypertension (ISAH). The comparison of two ethnic groups of the population has showed higher levels of systolic and diastolic blood pressure (SBP and DBP) in the group of patients of non-indigenous nationality, rather than Yakut patients. Correlation was recorded in the group of non-indigenous patients as they age. Significant increase in the level of SBP was identified in the group of senile and long-livers than in the elderly. Detection of ECG signs of LVH showed the lowest specificity of Cornell voltage criterion comparing to Sokolow-Lyon criterion with its more often occurrence. ECG-signs of left ventricle hypertrophy are significantly more often established by Sokolow-Lyon criterion for men, Cornell voltage—for women. Correlation has been found between the presence of LVH and combination of Cornell voltage criterion with both Gubner-Ungerleider and Sokolow-Lyon criteria.展开更多
Background Glycoprotein （GP） Ⅱb/Ⅲa antagonist has been shown its efficacy and safety in high-risk patients with acute coronary syndrome （ACS） who underwent percutaneous coronary intervention （PCI）. Whether GP...Background Glycoprotein （GP） Ⅱb/Ⅲa antagonist has been shown its efficacy and safety in high-risk patients with acute coronary syndrome （ACS） who underwent percutaneous coronary intervention （PCI）. Whether GP Ⅱb/Ⅲa antagonist is as effective and safe in older patients （ ≥ 65 years old ） as in younger patients remains unclear. Objectives Our objective was to determine whether GP Ⅱb/Ⅲa antagonist tirofiban was effective and safe in patients aged ≥65 years who underwent PCI. Methods From September 2006 to August 2008, 622 patients with non-ST-elevation ACS （NSTE ACS） were randomized to receive either tirofiban （n = 313 ） or placebo （n = 309）. The infusion duration was 48 hours for both groups. Incidence of major adverse cardiac events （MACE） was assessed at 180 days. Incidence of bleeding was monitored through 24 hours after trial therapy was discontinued. Results The incidence of MACE for the tirofiban group versus the placebo group was 7.3% vs 12. 6% （P 〈0. 05）. Among these MACE, death rate was 2.6% vs 4. 6 % （ P = 0. 198 ）, non-fatal MI was 3.8 % vs 6.5 % （ P = 0. 150）, and target vessel revascularization was 1.3% vs 1.6% （P =0. 751 ）, in the two groups, respectively. The total bleeding rate for the tirofiban group versus the placebo group was 28.1% vs 6.8% （P 〈0. 05 ）. The TIMI major and minor bleeding rates for the tirifiban versus the placebo group were 2.2% vs 1.6% （ P 〉 0. 05 ） and 25.9% vs 5.2% （ P 〈 0. 05 ）, respectively. Conclusions Tirofiban appears to be effective and safe in older patients with ACS who underwent PCI.展开更多
文摘As a result of research, high prevalence of arterial hypertension has been identified in the group of patients with coronary heart disease aged 60 and older. Most often, occurring form of arterial hypertension among geriatric patients is isolated systolic arterial hypertension (ISAH). The comparison of two ethnic groups of the population has showed higher levels of systolic and diastolic blood pressure (SBP and DBP) in the group of patients of non-indigenous nationality, rather than Yakut patients. Correlation was recorded in the group of non-indigenous patients as they age. Significant increase in the level of SBP was identified in the group of senile and long-livers than in the elderly. Detection of ECG signs of LVH showed the lowest specificity of Cornell voltage criterion comparing to Sokolow-Lyon criterion with its more often occurrence. ECG-signs of left ventricle hypertrophy are significantly more often established by Sokolow-Lyon criterion for men, Cornell voltage—for women. Correlation has been found between the presence of LVH and combination of Cornell voltage criterion with both Gubner-Ungerleider and Sokolow-Lyon criteria.
文摘Background Glycoprotein （GP） Ⅱb/Ⅲa antagonist has been shown its efficacy and safety in high-risk patients with acute coronary syndrome （ACS） who underwent percutaneous coronary intervention （PCI）. Whether GP Ⅱb/Ⅲa antagonist is as effective and safe in older patients （ ≥ 65 years old ） as in younger patients remains unclear. Objectives Our objective was to determine whether GP Ⅱb/Ⅲa antagonist tirofiban was effective and safe in patients aged ≥65 years who underwent PCI. Methods From September 2006 to August 2008, 622 patients with non-ST-elevation ACS （NSTE ACS） were randomized to receive either tirofiban （n = 313 ） or placebo （n = 309）. The infusion duration was 48 hours for both groups. Incidence of major adverse cardiac events （MACE） was assessed at 180 days. Incidence of bleeding was monitored through 24 hours after trial therapy was discontinued. Results The incidence of MACE for the tirofiban group versus the placebo group was 7.3% vs 12. 6% （P 〈0. 05）. Among these MACE, death rate was 2.6% vs 4. 6 % （ P = 0. 198 ）, non-fatal MI was 3.8 % vs 6.5 % （ P = 0. 150）, and target vessel revascularization was 1.3% vs 1.6% （P =0. 751 ）, in the two groups, respectively. The total bleeding rate for the tirofiban group versus the placebo group was 28.1% vs 6.8% （P 〈0. 05 ）. The TIMI major and minor bleeding rates for the tirifiban versus the placebo group were 2.2% vs 1.6% （ P 〉 0. 05 ） and 25.9% vs 5.2% （ P 〈 0. 05 ）, respectively. Conclusions Tirofiban appears to be effective and safe in older patients with ACS who underwent PCI.
